Verantwoord innoveren

GMO safety
Synthetic biology
Adaptive Risk Assessment

Monsanto has entered into a licensing deal with the Broad Institute of MIT and Harvard to access CRISPR-Cas9 gene-editing technology for agricultural use. The agreement excludes use of the technology for gene drives and the development of sterile seeds.


Source: The Scientist, September 2016.


​​ Kantoor:
+31 (0)343 51 47 61
+31 (0)6 238 68 017

Diederichslaan 25
3971 PA Driebergen